KR20070064619A - 치료 단백질 기반 분자들의 신규한 류 - Google Patents

치료 단백질 기반 분자들의 신규한 류 Download PDF

Info

Publication number
KR20070064619A
KR20070064619A KR1020077008112A KR20077008112A KR20070064619A KR 20070064619 A KR20070064619 A KR 20070064619A KR 1020077008112 A KR1020077008112 A KR 1020077008112A KR 20077008112 A KR20077008112 A KR 20077008112A KR 20070064619 A KR20070064619 A KR 20070064619A
Authority
KR
South Korea
Prior art keywords
sialidase
protein
seq
domain
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077008112A
Other languages
English (en)
Korean (ko)
Inventor
팡 팡
마이클 마라크호브
Original Assignee
팡 팡
마이클 마라크호브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 팡 팡, 마이클 마라크호브 filed Critical 팡 팡
Publication of KR20070064619A publication Critical patent/KR20070064619A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020077008112A 2004-09-10 2005-07-21 치료 단백질 기반 분자들의 신규한 류 Withdrawn KR20070064619A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/939,262 2004-09-10
US10/939,262 US7807174B2 (en) 2002-11-22 2004-09-10 Class of therapeutic protein based molecules

Publications (1)

Publication Number Publication Date
KR20070064619A true KR20070064619A (ko) 2007-06-21

Family

ID=36060467

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077008112A Withdrawn KR20070064619A (ko) 2004-09-10 2005-07-21 치료 단백질 기반 분자들의 신규한 류

Country Status (16)

Country Link
US (2) US7807174B2 (https=)
EP (4) EP3241898B1 (https=)
JP (2) JP4764881B2 (https=)
KR (1) KR20070064619A (https=)
CN (2) CN101426906B (https=)
AU (1) AU2005285461B2 (https=)
BR (1) BRPI0515646B8 (https=)
CA (2) CA2578050C (https=)
DK (3) DK3241898T3 (https=)
ES (3) ES2626845T3 (https=)
IL (3) IL181779A (https=)
PT (3) PT1786902E (https=)
RU (1) RU2468080C2 (https=)
TR (1) TR201905393T4 (https=)
WO (1) WO2006031291A2 (https=)
ZA (1) ZA200702915B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
CA2506526C (en) * 2002-11-22 2017-04-18 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
WO2006051864A1 (ja) * 2004-11-10 2006-05-18 Hitachi Chemical Co., Ltd. 接着補助剤付金属箔及びそれを用いたプリント配線板
EP1954296A4 (en) * 2005-10-25 2010-09-15 Mnd Diagnostic Ltd COMPOSITIONS FOR DETECTING INFLUENZA VIRUSES AND KITS AND METHODS BASED ON THE USE OF SAID COMPOSITIONS
AU2013237761B8 (en) * 2006-01-24 2015-06-04 Ansun Biopharma, Inc. Technology for preparation of macromolecular microspheres
AU2015215955B2 (en) * 2006-01-24 2016-12-01 Ansun Biopharma, Inc. Technology for preparation of macromolecular microspheres
CN101404980A (zh) 2006-01-24 2009-04-08 耐百生物制药有限公司 大分子微球的制备技术
US8273381B1 (en) * 2006-04-14 2012-09-25 Auburn University Compositions for and methods of controlling olfactory responses to odorants
US20100143972A1 (en) * 2006-12-14 2010-06-10 Horswill Alexander R Method of Making Cyclic Polypeptides with Inteins
CA2676686C (en) * 2007-02-20 2015-12-15 Dsm Ip Assets B.V. Novel sialidase
ES2550755T3 (es) 2007-08-03 2015-11-12 Romark Laboratories, L.C. Compuestos de tiazolida sustituidos con alquilsulfonilo
NZ596538A (en) 2009-05-12 2014-04-30 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
CN108042535A (zh) 2009-06-26 2018-05-18 罗马克实验室有限公司 用于治疗流感的化合物和方法
CN102575242B (zh) * 2009-07-31 2015-03-25 丹尼斯科美国公司 具有经修饰的前原区域的蛋白酶
AU2010315024B2 (en) * 2009-11-06 2015-02-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract
WO2013123521A1 (en) * 2012-02-17 2013-08-22 Nexbio, Inc. Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients
EP2866792A4 (en) 2012-06-28 2016-08-17 Ansun Biopharma Inc MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
WO2014005107A2 (en) * 2012-06-28 2014-01-03 Ansun Biopharma, Inc. Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture
BR112015015182B1 (pt) 2012-12-24 2023-12-26 Coagulant Therapeutics Corporation Variante polipeptídica isolada do fator vii, seu método de preparação e seu uso, e composições farmacêuticas e seus usos
CA2906593C (en) 2013-03-15 2022-11-15 Ansun Biopharma, Inc. Method of protein purification
BR112015021866A2 (pt) 2013-03-15 2017-08-29 Bayer Healthcare Llc Domínios de gla como agentes direcionadores
WO2014197485A1 (en) * 2013-06-03 2014-12-11 Ansun Biopharma, Inc. Anti-viral therapeutic for infection of the eye
US10300116B2 (en) 2013-06-10 2019-05-28 Ansun Biopharma, Inc. Treatment for BK polyomavirus infection
US20160120961A1 (en) * 2013-06-10 2016-05-05 Ansun Biopharma, Inc. Treatment of merkel cell polyomavirus infection
WO2015184356A1 (en) 2014-05-30 2015-12-03 Ansun Biopharma, Inc. Treatment of middle east respiratory syndrome coronavirus
WO2016044656A1 (en) 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016115616A1 (en) * 2015-01-21 2016-07-28 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Inhibition of cellular proteases as treatment for influenza
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017015491A1 (en) * 2015-07-21 2017-01-26 Thomas Jefferson University Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
EP3458085B1 (en) 2016-05-20 2022-12-07 Octapharma AG Glycosylated vwf fusion proteins with improved pharmacokinetics
CN109641038A (zh) 2016-07-01 2019-04-16 小利兰·斯坦福大学理事会 靶向细胞表面编辑的共轭物
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN111183220B (zh) 2017-05-26 2024-03-22 杰诺维斯公司 用于聚糖分析的工具
EP3679129A1 (en) * 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. A method of intracellular delivery
EP3735458A4 (en) 2018-01-03 2022-04-27 Palleon Pharmaceuticals Inc. RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
GB201800274D0 (en) * 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
GB201803197D0 (en) 2018-02-27 2018-04-11 Pneumagen Ltd Viral treatment
WO2020018996A2 (en) * 2018-07-20 2020-01-23 Ansun Biopharma, Inc. Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
CN109991649B (zh) * 2019-03-26 2021-04-06 华中科技大学 一种制备无机闪烁体膜的方法
JP7343890B2 (ja) * 2019-04-26 2023-09-13 国立大学法人東海国立大学機構 シアリダーゼ活性を有する酵素剤及びその利用
CN110038122A (zh) * 2019-05-23 2019-07-23 武汉真福医药股份有限公司 枯草杆菌纤溶酶在治疗支气管炎药物中的应用
US12245754B2 (en) 2019-07-03 2025-03-11 Aillis Inc. Pharmaceutical composition for treating influenza virus infections
CN111450236B (zh) * 2020-02-25 2023-04-07 西北大学 一种用于阻断冠状病毒感染的制剂
WO2021217053A1 (en) * 2020-04-24 2021-10-28 Rezolute, Inc. Plasma kallikrein inhibitors for the treatment of ards and related conditions
US20230218794A1 (en) * 2020-06-10 2023-07-13 The Penn State Research Foundation Process and system to lessen human coronavirus transmission and spread
WO2022147480A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Oncolytic virus encoding sialidase and multispecific immune cell engager
CN117836432A (zh) * 2021-06-09 2024-04-05 微生物机器公司 用于检测患病细胞的工程化微生物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3439089A (en) 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
DE286239T1 (de) * 1987-03-10 1994-02-24 New England Biolabs Inc Herstellung und Reinigung eines Proteins, das mit einem Bindungsprotein fusioniert ist.
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
US5376633A (en) 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
US5985859A (en) 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
CN1143387A (zh) * 1994-06-14 1997-02-19 吉斯特·布罗卡迪斯股份有限公司 热稳定性木聚糖酶
CN100409844C (zh) * 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
GB9513683D0 (en) * 1995-07-05 1995-09-06 Ciba Geigy Ag Products
WO1998031817A2 (en) 1997-01-14 1998-07-23 Hopital Sainte-Justine Human lysosomal sialidase and therapeutic uses thereof
US6251392B1 (en) 1997-10-20 2001-06-26 Epicyte Pharmaceuticals, Inc. Epithelial cell targeting agent
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20020025320A1 (en) 1999-08-20 2002-02-28 Prosper Boyaka Sialidases as mucosal adjuvants
CN1405562A (zh) * 2002-10-24 2003-03-26 肖洪武 一种唾液酸酶测定试剂
CA2506526C (en) 2002-11-22 2017-04-18 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
DE10258400A1 (de) * 2002-12-13 2004-06-24 N.V. Nutricia Trans-Sialidasen aus Trypanosoma congolense
CN101404980A (zh) 2006-01-24 2009-04-08 耐百生物制药有限公司 大分子微球的制备技术

Also Published As

Publication number Publication date
CN104017787A (zh) 2014-09-03
WO2006031291A2 (en) 2006-03-23
BRPI0515646B8 (pt) 2021-05-25
CN101426906A (zh) 2009-05-06
IL241227B (en) 2020-05-31
EP3241898A1 (en) 2017-11-08
PT3241898T (pt) 2019-05-20
ZA200702915B (en) 2008-11-26
EP3241898B1 (en) 2019-01-23
IL207957A (en) 2016-10-31
CN101426906B (zh) 2013-06-26
EP1786902A2 (en) 2007-05-23
BRPI0515646A8 (pt) 2017-04-04
PT1786902E (pt) 2015-12-22
PT3018204T (pt) 2017-07-13
ES2554787T3 (es) 2015-12-23
EP3018204A1 (en) 2016-05-11
US20050112751A1 (en) 2005-05-26
JP4764881B2 (ja) 2011-09-07
IL241227A0 (en) 2015-11-30
CA2823429C (en) 2019-06-04
HK1201562A1 (en) 2015-09-04
IL207957A0 (en) 2010-12-30
DK3241898T3 (en) 2019-04-29
EP1786902B1 (en) 2015-09-09
ES2721172T3 (es) 2019-07-29
HK1224329A1 (en) 2017-08-18
CA2578050C (en) 2015-04-21
WO2006031291A3 (en) 2009-04-16
CA2823429A1 (en) 2006-03-23
EP1786902A4 (en) 2009-12-09
EP3530734A1 (en) 2019-08-28
BRPI0515646B1 (pt) 2020-10-13
CA2578050A1 (en) 2006-03-23
EP3018204B1 (en) 2017-04-12
IL181779A (en) 2015-10-29
JP5307082B2 (ja) 2013-10-02
JP2008512117A (ja) 2008-04-24
IL181779A0 (en) 2007-07-04
AU2005285461A1 (en) 2006-03-23
DK3018204T3 (en) 2017-07-31
US7645448B2 (en) 2010-01-12
RU2007112502A (ru) 2008-10-20
US7807174B2 (en) 2010-10-05
CN104017787B (zh) 2017-03-29
RU2468080C2 (ru) 2012-11-27
BRPI0515646A (pt) 2008-07-15
JP2010279366A (ja) 2010-12-16
US20090142327A1 (en) 2009-06-04
DK1786902T3 (en) 2015-10-19
AU2005285461B2 (en) 2011-03-03
TR201905393T4 (tr) 2019-05-21
ES2626845T3 (es) 2017-07-26

Similar Documents

Publication Publication Date Title
DK3241898T3 (en) HIS UNKNOWN CLASS OF MOLECULES BASED ON THERAPEUTIC PROTEINS
US10525109B2 (en) Class of therapeutic protein based molecules
HK1246351B (en) A novel class of therapeutic protein based molecules
HK1246351A1 (en) A novel class of therapeutic protein based molecules
HK1224329B (en) A novel class of therapeutic protein based molecules
HK1201562B (en) A novel class of therapeutic protein based molecules
HK1128935B (en) A novel class of therapeutic protein based molecules
HK1128935A (en) A novel class of therapeutic protein based molecules

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070410

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid